This HTML5 document contains 37 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05885/identifier/chemspider/
dctermshttp://purl.org/dc/terms/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05885/identifier/pubchem-compound/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05885/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05885
rdf:type
n3:Drug
n3:description
UCB 44212 is indicated for the treatment of various types seizure disorders such as epilepsy, a neurological dysfunction in which excessive surges of electrical energy are emitted in the brain, and other disorders.
n3:generalReferences
# Bennett B, Matagne A, Michel P, Leonard M, Cornet M, Meeus MA, Toublanc N: Seletracetam (UCB 44212). Neurotherapeutics. 2007 Jan;4(1):117-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17199025 # Bialer M: New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16732716
n3:group
investigational
n3:indication
Investigated for use/treatment in epilepsy.
owl:sameAs
n7:DB05885
dcterms:title
UCB 44212
adms:identifier
n9:9942725 n10:8118337 n11:DB05885
n3:mechanismOfAction
UCB 44212 is effective in controlling the seizures associated with epilepsy. Some anticonvulsants are thought to generally depress central nervous system (CNS) function. Others, such as GABA inhibitors, are thought to target specific neurochemical processes, suppress excess neuron function, and regulate electrochemical signals in the brain.
n3:IUPAC-Name
n4:271B4880-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4886-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4885-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4882-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4883-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4884-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B487E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B487C-363D-11E5-9242-09173F13E4C5 n4:271B487F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B487D-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B488C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B488D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4887-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4888-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B488A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4889-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B488B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4892-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4894-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4895-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4891-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4890-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4893-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4881-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B488E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B488F-363D-11E5-9242-09173F13E4C5